MetaCap

Ironwood Pharmaceuticals (IRWD) vs Mentari Therapeutics (MTRI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mentari Therapeutics is the larger company by market cap ($856.9 million vs $778.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRWD+7.80%MTRI+0.68%
+39%+8%-23%
Aug 17, 20261 yearNov 20, 2026
IRWD+9.56%MTRI+0.68%
+30%+4%-22%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRWD versus MTRI key metrics
MetricIRWDMTRI
Share price$4.70$14.70
Market cap$778.09M$856.94M
1-day change-0.21%-3.57%
YTD return+39.47%—
1-year return+48.73%—
5-year return-57.89%—
P/E ratio (TTM)5.22—
Forward P/E3.00—
EPS (TTM)$0.90—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$296.15M—
Revenue growth (YoY)-15.72%—
Net income (latest FY)$24.02M—
Operating margin33.26%—
Net margin8.11%—
52-week high$5.78$23.30
52-week low$2.95$5.75
Distance from 52-week high-18.69%-36.91%
Analyst consensusbuystrong_buy
Avg. price target upside+31.49%—
Average volume2.15M19.42K
Shares outstanding165.55M58.30M
Employees100—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Ironwood Pharmaceuticals

IRWD stock →

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Mentari Therapeutics

MTRI stock →

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.

Health Care · Biotechnology: Pharmaceutical Preparations

IRWD vs MTRI FAQ

Which is bigger, Ironwood Pharmaceuticals or Mentari Therapeutics?

Mentari Therapeutics (MTRI) is larger, with a market capitalization of $856.94M compared with $778.09M for Ironwood Pharmaceuticals (IRWD).

Are Ironwood Pharmaceuticals and Mentari Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons